医药生物行业 2024&2025Q1 财报总结：创新与出海驱 动结构性机会 20250511 摘要 • 医药行业估值处于近十年低位，申万医药行业市盈率约为 26 倍，远低于 近十年中枢估值 36 倍和最高估值 73 倍，仅为申万行业平均估值的 76%，具备估值修复空间，但需关注集采政策和创新药入院进度。 • 2024 年医药生物行业营收同比下降 1.4%，归母净利润同比下降 14.4%。但 2025 年 Q1 数据显示，行业营收环比提升 1.78%，归母净利 润环比大幅提升 1,379%，显示出复苏迹象，其中医疗服务和原料药板块 表现突出。 • 化学制剂板块表现最佳，2024 年收入同比增长 2.1%，规模同比增长 35%，归母净利润同比唯一实现正增长，受益于创新政策利好和集采政策 缓和预期。中药板块跌幅最大，但净利率有所恢复，在特定疾病领域仍具 优势。 • 中国制药企业全球化加速，2024 年跨境许可交易总额超 423 亿美元， 2025 年 Q1 中国医药交易金额占全球一半以上，同比增长超 200%，成 为全球医药交易的重要引擎，尤其在肥胖、中枢神经系统等领域表现突出。 Q&A 2025 年医药生物行业的 ...

Group 1 - The private equity issuance market has seen a significant increase in activity, with nearly 3,500 new private securities investment funds registered this year, representing a nearly 40% growth compared to the same period last year [1] - NIO plans to issue H-shares at a maximum price of 263 HKD per share, with the pricing expected between May 13 and May 16, and trading to commence on May 20 [1] - A trend of consumer companies going public overseas has emerged, with several new consumption brands planning listings in Hong Kong and the US, driven by the need for international expansion and brand enhancement [1] Group 2 - Shanghai Ladder Medical Technology has successfully conducted a clinical trial of an invasive brain-computer interface system, allowing a participant to control a game using thoughts after implant surgery [2] - Samsung has reportedly reached an agreement with major clients to increase DRAM prices, with DDR4 prices rising by double-digit percentages and DDR5 prices increasing by single-digit percentages [2] - Polestar is recalling 3,664 vehicles in the US due to a rearview camera issue that may reduce driver visibility, with software updates planned to address the problem [2] Group 3 - Specialized Medical Company in Saudi Arabia successfully completed a $500 million IPO, with all shares sold within hours, indicating strong demand [3] - Mirxes Holding Company Limited has passed the listing hearing at the Hong Kong Stock Exchange, focusing on miRNA technology for cancer screening [4] Group 4 - Huiyuan Juice has issued a statement refuting rumors about its financial difficulties, emphasizing that such claims are malicious and damaging to its reputation [5] - Hualan Biological Engineering announced that its major shareholder plans to reduce its stake by up to 3% within three months [6] - Pilin Bio received an administrative regulatory decision from the Shanxi Securities Regulatory Bureau due to internal control deficiencies and inaccurate information disclosure [7] Group 5 - ST Jinke has received court approval for its restructuring plan, allowing the company and its subsidiary to enter the execution phase of the plan [8]

Core Viewpoint - Hemophilia is a hereditary bleeding disorder primarily treated through factor replacement therapy, with significant advancements in drug development leading to increased demand and market growth in China [1][6][20]. Industry Definition and Categories - Hemophilia is characterized by a deficiency in clotting factors, leading to prolonged bleeding tendencies, and can be classified into Hemophilia A and B, with A being more prevalent [2][3]. Current Industry Status - The demand for hemophilia drugs is on the rise due to advancements in diagnosis and treatment, with a projected demand of 5.8236 million doses in 2024 and 7.3154 million doses in 2025, reflecting a growing market size from 5.361 billion yuan in 2024 to 5.856 billion yuan in 2025 [6][9]. Market Competition Landscape - Major domestic companies in the hemophilia drug market include Beijing Shenzhou Cell Engineering, Shandong Taibang Biological Products, Henan Hualan Biological Engineering, and Shanghai Raist Blood Products, among others [13][14]. Industry Development Trends - The hemophilia drug industry is expected to benefit from technological innovations and increased awareness, leading to a broader market outlook as more patients can afford treatment and government support for rare diseases grows [20].

Group 1 - Palin Bio received an administrative regulatory decision from Shanxi Securities Regulatory Commission due to internal control deficiencies and inaccurate information disclosure, leading to warnings for its management [1] - Maiwei Bio's chairman Liu Datao is under investigation for suspected short-term trading, which may affect investor confidence and the company's reputation despite claims of no impact on daily operations [2] - Gilead Sciences reached a settlement of $202 million with the U.S. government over kickback allegations, which could negatively impact investor confidence and the company's reputation if compliance issues are not addressed [3] Group 2 - Rongchang Bio's ADC drug, Vidisicimab, received approval from NMPA for treating HER2-positive advanced breast cancer, marking a significant market opportunity and potential revenue increase for the company [4] - Hansoh Pharma's innovative drug Amivantamab received NMPA approval for a new indication, expanding its market potential and likely boosting sales and investor interest [5]

Macro Insights - The first large listed real estate company in China, Jinke Co., has achieved significant progress in its judicial reorganization [2] - Several small and medium-sized banks have lowered deposit interest rates, with some banks experiencing a "negative interest rate" phenomenon [2] - Apple has officially adjusted the prices of its iPhone 16 Pro Max, reducing all storage versions by $160 [2] - Major shareholders of companies like Hualan Biological Engineering are planning to reduce their stakes [2] Financial Alerts - Shandong Molong's stock price surged by 450% before major shareholders sold off 136 million shares, representing 17% of total shares [5] - Jingwei Huikai announced that two shareholders plan to reduce their holdings by no more than 3% [6] - Jiahe Meikang's shareholder Hongyun Jiukang intends to reduce its stake by no more than 1.3% [7] - Leiwei and Baichuan Energy also reported plans for minor stake reductions by their shareholders [8][9] - Qujiang Cultural Tourism's controlling shareholder's 4.7% stake is set to be auctioned judicially, but it will not affect the company's operations [13] Industry Alerts - The Chinese automotive industry, which has been the world's largest for 14 consecutive years, faces challenges due to long payment terms and "consignment systems," putting pressure on small and medium-sized parts suppliers [19] - After the May Day holiday, pig prices remained stable, with the market showing signs of weakness, indicating that the traditional peak season is not performing as expected [20]

Mergers and Acquisitions - *ST Jinke and its wholly-owned subsidiary's restructuring plan has been approved by the court [1] Performance Disclosure - Yisheng Shares reported a 7.28% year-on-year decline in sales revenue for white feather broiler chicks in April, with sales quantity at 48.932 million and revenue at 141 million yuan [2] Share Buyback and Increase - Guizhou Tire's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan [3] - Jiadu Technology will complete the cancellation of 10.2049 million repurchased shares on May 12, 2025, changing the purpose of these shares from employee stock ownership plan to capital reduction [4] Risk Matters - Hualan Shares announced that shareholder Ruizhong Life Insurance plans to reduce its stake by up to 3%, amounting to a maximum of 3.789267 million shares [5] - Dongpeng Holdings' shareholders plan to collectively reduce their stake by up to 1.5% of the company's total share capital [6] - Huilong Pharmaceutical's shareholder Shanghai Shuangsa plans to reduce its stake by up to 2.997%, equating to a maximum of 12.6956 million shares [7] Regulatory Actions - Pilin Bio received an administrative regulatory decision from the Shanxi Securities Regulatory Bureau, which includes corrective measures [8]

证券代码：000403 证券简称：派林生物 公告编号：2025-022 派斯双林生物制药股份有限公司 关于收到山西证监局行政监管措施决定书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）于近日收到中国证券监督管 理委员会山西监管局（以下简称"山西证监局"）出具的《关于对派斯双林生物制药 股份有限公司采取责令改正措施的决定》（[2025]18 号）和《关于对李昊、荣先奎、 赵玉林、付绍兰、袁华刚采取出具警示函措施的决定》（[2025]19 号）（以下简称"《行 政监管措施决定书》"）。现将相关内容公告如下： 一、 行政监管措施决定书的具体内容 经查，公司存在以下违规行为： 一是公司子公司与个别客户及推广商针对部分销售事项签署了附带责任义务条 款的补充协议、备忘录等，但相关协议签署及承诺安排未纳入公司内控管理体系，公 司内部对业务及合同管控存在缺陷，导致相关信息披露不准确。二是公司部分重大事 项未进行内幕信息知情人登记，部分内幕信息知情人登记档案不完整。 上述行为违反了《企业内部控制应用指引第 9 号——销 ...

Market Overview - The A-share market saw all three major indices rise on Tuesday, with the Shanghai Composite Index up 1.13%, the Shenzhen Component Index up 1.84%, and the ChiNext Index up 1.97%. The total trading volume in the Shanghai and Shenzhen markets reached 13,359.84 billion yuan [2][6] - In the Shenwan industry sector, computer, communication, and comprehensive industries led the gains, while the banking sector lagged behind. Concept sectors such as controllable nuclear fusion, rare earth permanent magnets, and Huawei Pangu saw significant increases, while sectors like recombinant protein and super brands lagged [2][6] Important News - The State Council Information Office held a press conference on May 7, 2025, to discuss a "package of financial policies to support market stability and expectations" [3][6] - In the first quarter of 2025, A-share listed companies reported strong performance, with 4,068 out of 5,391 companies disclosing profits, representing a profitability rate of 75.46%. This indicates enhanced market vitality and reflects strong economic momentum in China [3][6] Industry Insights - In the consumer goods manufacturing sector, profits have improved across several sub-industries. In March 2025, the total profit of industrial enterprises above designated size reached 15,093.6 billion yuan, a year-on-year increase of 0.8% [7][8] - The agricultural and sideline food processing industry saw a profit increase of 40.3% year-on-year, while other sectors like furniture and paper experienced significant declines [8][9] - The advanced packaging sector is expected to enhance profitability, with revenue exceeding 100 billion yuan in Q4 2024, indicating a positive outlook for the industry [9][19] Company-Specific Analysis - For the company Palin Bio, total revenue for 2024 was 2.655 billion yuan, a 14% increase, while Q1 2025 revenue was 375 million yuan, a 14% decrease due to production capacity expansion [11][12] - Tian Tan Bio reported a total revenue of 6.032 billion yuan in 2024, a 16.44% increase, but a 22.90% decrease in Q1 2025 due to price declines [15][16] - Long Electric Technology achieved a total revenue of 35.962 billion yuan in 2024, a 21.24% increase, with Q1 2025 revenue reaching 9.335 billion yuan, a 36.44% increase [18][21] - China Resources Sanjiu reported total revenue of 27.617 billion yuan in 2024, an 11.63% increase, but a 6.04% decrease in Q1 2025 [26][27] - Pianzaihuang's total revenue for 2024 was 10.788 billion yuan, a 7.25% increase, with Q1 2025 revenue at 3.142 billion yuan, a 0.92% decrease [30][31]

降本增效显著，采浆快速增长 ——派林生物 2024 年报&2025 年一季报点评 核心观点 盈利预测与投资建议 ⚫ 考虑到公司产能扩增带来的短期影响，我们下调盈利预期，预测公司 2025-2027 年 每股收益分别为 1.23、1.42、1.60 元（原预测值 2025-2026 年分别为 1.28/1.47 元），参考可比公司平均市盈率，我们给予公司 2025 年 23 倍 PE 估值，对应目标价 28.29 元，维持"买入"评级。 风险提示 ⚫ 行业估值水平波动的风险；采浆量不达预期风险；新品上市不达预期风险；行业政 策变动风险；商誉减值风险等。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 2,329 | 2,655 | 3,217 | 3,637 | 4,043 | | 同比增长 (%) | -3.2% | 14.0% | 21.2% | 13.1% | 11.2% | | 营业利润(百万元) | 695 | 880 | 1,018 | 1 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company has shown significant cost reduction and efficiency improvement, leading to rapid growth in plasma collection [1] - The company has adjusted its earnings forecast for 2025-2027, predicting earnings per share of 1.23, 1.42, and 1.60 yuan respectively, with a target price of 28.29 yuan based on a 23x PE valuation for 2025 [2] Financial Performance Summary - Revenue for 2023 was 2,329 million yuan, with a projected increase to 2,655 million yuan in 2024 (+14.0%), and further growth to 3,217 million yuan in 2025 (+21.2%) [4] - Operating profit is expected to rise from 695 million yuan in 2023 to 880 million yuan in 2024 (+26.6%), and to 1,018 million yuan in 2025 (+15.6%) [4] - Net profit attributable to the parent company is forecasted to grow from 612 million yuan in 2023 to 745 million yuan in 2024 (+21.8%), reaching 899 million yuan in 2025 (+20.6%) [4] - The company achieved a net profit margin of 28.1% in 2024, an increase of 1.8 percentage points from the previous year [8] - The company aims to collect over 1,600 tons of plasma in 2025, building on a collection of over 1,400 tons in 2024 [8]